Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results
Joel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C Liu, Michael E Abram, Huyen Cao, Javier Szwarcberg, Joel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C Liu, Michael E Abram, Huyen Cao, Javier Szwarcberg
Abstract
Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.
Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.
Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.
Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.
Source: PubMed